Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
36
SNBIF Quote, Financials, Valuation and Earnings
Last price:
$4.65
Seasonality move
:
7.19%
Day range:
$4.65 - $4.65
52-week range:
$3.80 - $5.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
78.05x
P/B ratio:
81.95x
Volume:
--
Avg. volume:
159
1-year change:
17.72%
Market cap:
$329.8M
Revenue:
--
EPS (TTM):
-$0.28
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, SanBio has -- downside to fair value with a price target of -- per share.
SNBIF vs. S&P 500
-
Over the past 5 trading days, SanBio has underperformed the S&P 500 by -1.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
SanBio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
SanBio revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter SanBio reported revenues of --.
Earnings Growth
-
SanBio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter SanBio reported earnings per share of -$0.08.
Enterprise value:
319.5M
EV / Invested capital:
--
Price / LTM sales:
78.05x
EV / EBIT:
--
EV / Revenue:
78.40x
PEG ratio (5yr expected):
-0.07x
EV / Free cash flow:
-3.49x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$65.3M | -$38M | -$22M | -$4.3M | -$6.2M | |
| EBITDA | -$9.8M | -$50.7M | -$18.5M | $809.8K | -$5.5M | |
| Diluted EPS | -$0.52 | -$0.69 | -$0.28 | -$0.01 | -$0.08 | |
| Period Ending | 2020-10-31 | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $96.8M | $71.2M | $38.3M | $28.1M | $16M | |
| Total Assets | $131M | $72.7M | $38.9M | $28.9M | $16.7M | |
| Current Liabilities | $24.8M | $18.3M | $7.8M | $6.4M | $4.2M | |
| Total Liabilities | $49.9M | $38.5M | $27.6M | $16.3M | $12.7M | |
| Total Equity | $81.2M | $34.2M | $11.3M | $12.6M | $4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-07-31 | 2023-07-31 | 2024-07-31 | 2023-07-31 | 2024-07-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$18.9M | -$10.8M | |
| Cash From Investing | -- | -- | -- | -$62.2K | -$23.9K | |
| Cash From Financing | -- | -- | -- | $3.3M | $2.2M | |
| Free Cash Flow | -$111.7M | -$104.9M | -$91.6M | -$18.9M | -$10.9M | |
SNBIF
Sector
Market Cap
$329.8M
$48.9M
Price % of 52-Week High
80.03%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
17.72%
-30.56%
Beta (5-Year)
-0.390
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$4.65
200-day SMA
Buy
Level
$3.97
Bollinger Bands (100)
Buy
Level
3.51 - 4.67
Chaikin Money Flow
Sell
Level
-2.1K
20-day SMA
Sell
Level
$5.05
Relative Strength Index (RSI14)
Sell
Level
46.44
ADX Line
Sell
Level
34.34
Williams %R
Buy
Level
-100
50-day SMA
Buy
Level
$4.33
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
77.1K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
Stock Forecast FAQ
In the current month, SNBIF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNBIF average analyst price target in the past 3 months is --.
-
Where Will SanBio Stock Be In 1 Year?
According to analysts, the consensus estimate is that SanBio share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About SanBio?
Analysts are divided on their view about SanBio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SanBio is a Sell and believe this share price will rise from its current level to --.
-
What Is SanBio's Price Target?
The price target for SanBio over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNBIF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for SanBio is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SNBIF?
You can purchase shares of SanBio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SanBio shares.
-
What Is The SanBio Share Price Today?
SanBio was last trading at $4.65 per share. This represents the most recent stock quote for SanBio. Yesterday, SanBio closed at $4.65 per share.
-
How To Buy SanBio Stock Online?
In order to purchase SanBio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
